10.1056/NEJMoa1603827 101
They may be broader metabolic and inflammatory disease-modifying therapies. The Study Has Some Limitations While the findings are promising, experts caution they dont prove GLP-1 medications directly caused the reductions in cardiovascular risk
Investigators reported increased tanning and higher eumelanin content in skin samples
doi: 10.1136/postgradmedj-2012-131068
These results demonstrate the potential for glucagon agonism, in addition to GLP-1, to both improve MASH and shift the needle on fibrosis, shared Dr Arun Sanyal, Professor of Medicine, Physiology and Molecular Pathology at Virginia Commonwealth University School of Medicine, and Principal Investigator of the trial
Worth it Very easy to use and effective so far